Keller Rohrback L.L.P. Investigates EpiPen Overcharges
October 06 2016 - 07:47PM
Business Wire
Attorney Advertising. Mylan N.V. (NASDAQ: MYL) may be
significantly overcharging patients for its EpiPen allergy shot.
Since Mylan acquired the drug in 2007, the price has increased
six-fold, from $100 to $600 for two doses. Yet Mylan pays only
$34.50 per pen.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161006006550/en/
Since Mylan acquired the drug in 2007,
the price has increased six-fold, from $100 to $600 for two doses.
Yet Mylan pays only $34.50 per pen. (Photo: Business Wire)
The EpiPen is a small device that automatically injects a dose
of the drug epinephrine into the thigh to counter life-threatening
reactions to allergens such as peanuts, shellfish and bee stings.
According to National Food Allergy Guidelines, a delay in
administering epinephrine can be life-threatening.
Mylan claims the price increase can be explained by more than $1
billion it has invested to improve the EpiPen. In 2009 Mylan
launched an upgraded version of the EpiPen; however, recent
independent studies show there is little change to the design of
the pen. PA Consulting Group, a UK-based technology consulting
firm, found that “it’s the same core device that’s been used for
some time.” The firm estimates the redesign may have only cost
Mylan several million dollars. In 2015, the EpiPen brought in over
$1 billion in sales for the company.
If you or someone you know has purchased an EpiPen since 2007,
please contact attorneys Michael
Meredith or Gretchen Freeman Cappio. Call 800-776-6044 or
email consumer@kellerrohrback.com.
Keller Rohrback L.L.P. has decades of experience helping
consumers and insureds fight back against fraud and abuse. Keller
Rohrback L.L.P. serves as lead and co-lead counsel in class action
lawsuits throughout the country. With offices in New York, Seattle,
Phoenix, Ronan, Oakland, and Santa Barbara, our Complex Litigation
Group is proud to offer its expertise to clients nationwide. Our
trial lawyers have obtained judgments and settlements on behalf of
clients in excess of seven billion dollars.
Attorney Advertising. Prior results do not guarantee a similar
outcome. Not licensed to practice law in all states. Please refer
to our website for details.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161006006550/en/
Keller Rohrback L.L.P.Michael Meredith or Gretchen
Freeman Cappio, Attorneys800-776-60441201 Third Avenue, Suite
3200Seattle, WA
98101consumer@kellerrohrback.comhttp://www.krcomplexlit.com
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Mar 2023 to Mar 2024